home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9407a.zip
/
M9470013.TXT
< prev
next >
Wrap
Text File
|
1994-07-02
|
2KB
|
37 lines
Document 0013
DOCN M9470013
TI Combined daily therapy with intravenous ganciclovir and foscarnet for
patients with recurrent cytomegalovirus retinitis.
DT 9409
AU Weinberg DV; Murphy R; Naughton K; Department of Ophthalmology,
Northwestern University Medical; School, Chicago, Illinois.
SO Am J Ophthalmol. 1994 Jun 15;117(6):776-82. Unique Identifier : AIDSLINE
MED/94256533
AB We treated seven patients (nine eyes) who had cytomegalovirus retinitis
with daily intravenous ganciclovir plus foscarnet. All patients had
demonstrated multiple progressions of retinitis on single-drug therapy,
and some were intolerant to induction doses of one or both medications.
Before combination therapy, the median number of progressions was five
per patient. The mean interval between progressions was 11 weeks, and
the mean interval before the final progression was four weeks. While
taking combination therapy, two patients showed progression after 14 and
34 weeks. Two patients showed no progression after 17 and 36 weeks of
follow-up. Three patients died after five, 14, and 23 weeks,
respectively, without progression of retinitis. In every patient, the
progression-free interval was longer during combination therapy than the
previous progression-free interval during single-drug therapy. In no
case was combination therapy stopped because of toxicity. Combination
therapy was fairly well tolerated and appeared to prolong the interval
to progression and to preserve vision in our patients.
DE Adult AIDS-Related Opportunistic Infections/*DRUG THERAPY Case Report
Comparative Study Cytomegalovirus Retinitis/*DRUG THERAPY Drug
Administration Schedule Drug Therapy, Combination Follow-Up Studies
Foscarnet/*ADMINISTRATION & DOSAGE/THERAPEUTIC USE
Ganciclovir/*ADMINISTRATION & DOSAGE/THERAPEUTIC USE Human Injections,
Intravenous Male Prognosis Recurrence Support, Non-U.S. Gov't
JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).